1585235-85-3

Basic information

• Product Name: C₂₅H₂₇F₁₇O₅
• Synonyms: C₂₅H₂₇F₁₇O₅
• CAS NO: 1585235-85-3
• Molecular Weight: 730.459
• Mol File: 1585235-85-3.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: C₂₅H₂₇F₁₇O₅(CAS DataBase Reference)
• NIST Chemistry Reference: C₂₅H₂₇F₁₇O₅(1585235-85-3)
• EPA Substance Registry System: C₂₅H₂₇F₁₇O₅(1585235-85-3)

Safety Data

• Hazardous Substances Data: 1585235-85-3(Hazardous Substances Data)

Upstream product

• 1585235-84-2 15-(4-(3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-heptadecafluorodecyl)phenyl)-1,1,1-triphenyl-2,5,8,11,14-pentaoxapentadecane 
• 2043-53-0 2-(n-perfluorooctyl)ethyl iodide 
• 589-87-7 1,4-bromoiodobenzene 
• 195324-88-0 1-(4'-bromophenyl)-3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-heptadecafluorodecane 
• 59016-93-2 p-hydroxymethylphenylboronic acid 
• 99768-12-4 4-methoxycarbonylphenylboronic acid 
• 495388-45-9 methyl 4-(3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-heptadecafluorodecyl)benzoate 
• 356055-77-1 (4-(3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-heptadecafluorodecyl)phenyl)methanol 
• 112-60-7 Tetraethylene glycol 

Downstream Products

• 1585235-86-4 27-(4-(3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-heptadecafluorodecyl)phenyl)-1,1,1-triphenyl-2,5,8,11,14,17,20,23,26-nonaoxaheptacosane 
• 1585235-87-5 ((3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-heptadecafluorodecyl)phenyl)-2,5,8,11,14,17,20,23-octaoxapentacosan-25-ol 
• 1585235-88-6 9-(4-(3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-heptadecafluorodecyl)phenyl)-1,1,1-triphenyl-2,5,8,11,14,17,20,23,26,29,32,35,38-tridecaoxanonatriacontane 

Relevant articles and documents

Fluorous synthesis of mono-dispersed poly(ethylene glycols)

Mono-dispersed poly(ethylene glycols) (PEGs) are of great value in the development of biopharmaceuticals. However, tedious synthesis limits the availability of mono-dispersed PEGs. To address this issue, a fluorous synthesis of mono-dispersed PEGs, discretely PEGylated surfactants and 19F magnetic resonance imaging (MRI) agents has been developed. During the synthesis, both fluorous and normal phase silica gel-based solid-phase extractions were successfully employed to simplify the purifications. This synthesis provided an easy access to valuable mono-dispersed PEGs and related molecules for biomedical application on multi-gram scales.